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Abstract
Since the middle of twentieth century, the concept of Quality of Life (QoL) has 
been a point of interest for many investigators and clinicians for different health 
and physiological issues. Menopause has not been an exemption of this, due to the 
increase of the life expectation, the importance of Women’s Health and the view 
of this period of life as important as the reproductive one. Many of us work, trying 
to offer these women with treatments, health solutions, and psychological tools to 
embrace and enjoy this new chapter in her life. In this chapter, we present a review 
of the QoL studies on this period and the new trends on treatments and help for 
these women on health problems, their mental and sexual well-being.
Keywords: menopause, quality of life, HRQoL, depression, sexuality, estrogen, 
ovarian, Climateric, GSM, vasomotor symptoms, MHT
1. Introduction
According to the World Health Organization, menopause is the permanent 
termination of menstruation as a result of the cessation of ovarian activity. The cli-
macteric phase is characterized by a decrease in ovarian activity, a decay in probable 
fertility, and the manifestation of various symptoms along with irregular intervals 
of menstruation. The period covers a fragment of premenopause and the parts of 
peri- and post-menopause, up until ancient age [1]. The transition into menopause 
is related to different physical and mental changes that may affect women’s health. 
Studies show that the physical, psychological, social, and sexual changes in meno-
pause have an adverse effect on women’s quality of life. It has been expressed that 
96% of women have menopausal complaints and their quality of life is affected not 
only physically and psychologically but also socially. It is reported that the quality 
of life of women is especially adversely affected in the perimenopausal and early 
postmenopausal periods [1].
Health-related quality of life (HRQoL) states to the effects of an individual’s 
physical condition on all phases of psychosocial functioning. For climacteric 
women, HRQoL is the particular universal standard that is critical for their daily 
well-being. Symptoms suffered throughout menopause and sociodemographic 
particularities have an influence in quality of life in postmenopausal women. In 
younger, symptomatic, postmenopausal women, HRQoL could be meaningfully 
reduced influenced by many supplementary, non-menopausal factors. However, 
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quality of life after menopause is influenced by many additional, non-menopausal 
factors [2]. Therapeutic methodologies that treat climacteric symptoms and all 
measures improving adverse non-hormonal factors could improve HRQoL among 
climacteric women. This includes marital and sexual therapy as well as psychosocial 
actions. Menopausal hormone therapy (MHT) may inverse this decline of HRQoL if 
it is due to postmenopausal estrogen deficiency [2].
2. Menopause
Menopause is a transitional period marked for many women by fluctuating 
physiological changes, which affect short-term quality of life such as vasomotor 
symptoms, sleep, and mood disorders; as well as for long-term changes such as 
genitourinary symptoms and decreased bone mineral density [3].
Four of five women experience physical and psychological symptoms around 
menopause with different degrees of severity and impact on quality of life [4]. 
Clinicians and women usually identify the transition to menopause by the onset of 
menstrual irregularities [5, 6]. This period called perimenopause is variable, but can 
range from 5 to 10 years before menopause.
Natural menopause is defined as the absence of menses for 12 months without a 
pathological cause. The average age of menopause is 51.4 years, but can vary accord-
ing to race, socioeconomic status, smoking habit, etc. [3]. During the menopausal 
transition, women experience: irregular menses, vasomotor symptoms, fluctuat-
ing fertility, sleep disturbances, depression and anxiety, genitourinary symptoms 
(including vaginal dryness), and sexual dysfunction.
Some studies show that 87% of women who report hot flashes experience daily 
symptoms, and a third of them experience more than 10 days [7, 8]. Its prevalence 
is approximately 40% in the early menopausal transition and 60–80% in the first 
2 years after menopause [9, 10]. African-American women have more vasomotor 
symptoms, while white women have more psychosomatic symptoms. Asian women 
have the least number of symptoms compared to the other races. In the Penn 
Ovarian Again Study (POAS), African-American women had more physiological 
symptoms (hot flashes, dizziness, urinary incontinence, and vaginal dryness) 
compared to white women [8, 9]. In the Study of Women’s Health Across the Nation 
(SWAN) and PSOAS, obese women had greater vasomotor symptoms [6, 11] and 
highly active smokers had a more than 60% greater likelihood of reporting severe 
hot flashes [12, 13]. Changes in menstrual bleeding patterns often signal the begin-
ning of the menopausal transition. The acronym PALM-COEIN is useful to recall 
the main causes in each category [14].
Cutoffs for the endometrial thickness measured by ultrasound vary by guide-
lines. The American College of Obstetricians and Gynecologists (ACOG) establishes 
normal endometrial thickness of 4 mm or less in postmenopausal women, while the 
American College of Radiology (ACR) suggests 5 mm or less; and in premenopausal 
women, it proposes a value of 16 mm or less as a cutoff [15]. Endometrial sampling 
using Pipelle has a sensitivity of 90% for endometrial cancer and 82% for atypical 
hyperplasia. Studies show regression of hyperplasia over 6 months when treated 
with levonorgestrel-releasing intrauterine device (LNG-IUD) or oral progesterone, 
10 mg, 10–14 days per month [3].
Management of acute bleeding, which is appropriate for medical treatment, 
options include: LNG-IUD, combined hormonal contraceptives, progestin therapy, 
tranexamic acid, and non-steroidal anti-inflammatory drugs. The surgical options 
are also varied, being able to perform dilatation and curettage, endometrial 
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ablation, uterine artery embolization, polypectomy, myomectomy, or hysterectomy, 
depending on the cause [3]. The North American Menopause Society (NAMS) 
recommends contraception for 12 months after the last menstrual period [3]. For 
women above 50-years old utilizing progestin-only contraceptives, follicle-stimu-
lating hormone (FSH) is able to measure to help identify menopause. The National 
Institute for Excellence in Health and Care (NICE) guidelines suggest measuring 
FSH 6 weeks apart, and if the amounts are greater than 30, then the contraceptive 
scheme might be discontinued after a year [16].
The Faculty of Sexual and Reproductive Healthcare (FSRH) recommends stop-
ping most methods at age 55, except for combined hormonal contraceptives and 
depot medroxyprogesterone acetate, which should be suspended at the age of 50 to 
avoid the increased risk of cardiovascular disease. FSRH also recommends women 
with a copper IUD placed after age 40 can remain use until menopause, and women 
with a 52 mg levonorgestrel-releasing IUD located after 45, can continue use until 
55. If the LNG-IUD is being used for endometrial protection instead of contracep-
tion, it should be replaced every 5 years [17].
Vulvovaginal symptoms affect up to 45% of postmenopausal women. Since 
2014, the International Society for the Study of Sexual Health of Women (ISSWSH) 
and the American Menopause Society (NAMS) have approved a new terminology 
for menopausal genitourinary and sexual symptoms, previously called vulvovaginal 
atrophy or atrophic vaginitis. This condition now labeled as genitourinary syn-
drome of menopause (GSM) as a result of the deficiency of estrogen effect not only 
on the vaginal mucosa but also on the urethra and sexual functioning [3]. The GSM 
usually become apparent 2 or 3 years after menopause and continues to worsen as 
the years go by, having an intense influence on the postmenopausal women’s quality 
of life, disturbing intimacy, satisfaction of sexual intercourse, sleep, and relation-
ships. Physical examination findings include pale and thin vaginal epithelium, a pH 
greater than 5 (normal pH is 3.5–4.5), and augmented parabasal cells on the matu-
ration index [3]. Prasterone, an intravaginal dehydroepiandrosterone preparation, 
was approved by the FDA in November 2016 and has also recognized efficacy in 
treatment of symptomatic GSM and dyspareunia [3]. Intravaginal estrogen therapy 
continues as the leader option for GSM. Local estrogen is marginally absorbed 
systemically and does not stimulate endometrial growth, so associated progesterone 
supplementation is not necessary. The recommended dosing using pills or cream 
normally starts with daily application until the symptoms improve and then weans 
down to anywhere between one and three times a week [3].
Women with an intact uterus on estrogen therapy should also receive adequate 
progesterone treatment to prevent endometrial hyperplasia and cancer. Micronized 
progesterone has a more favorable safety profile than synthetic progestins, but 
its twice daily dosing may be an obstacle in therapeutic compliance. Women who 
cannot tolerate the side effects of progesterone (fatigue, dysphoria, and fluid 
retention), an alternative agent for endometrial protection, is the selective estrogen 
receptor modulator, bazedoxifene. The LNG-IUD has also been used for this pur-
pose and has been shown to be equal to or superior to other progesterone formula-
tions in providing endometrial protection [3].
To minimize the risks of hormone therapy, the prescription should be with the 
lowest effective dose and the shortest duration necessary to improve the symptoms. 
There is no consensus on the recommended duration of hormone therapy or about 
its withdrawal, either with gradual dose reduction or abruptly. Approximately, 
half of the women will experience the return of vasomotor symptoms when they 
discontinue hormone therapy. The decision to discontinue hormone therapy should 
be individualized based on the patient’s symptoms and medical history [3].
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3. Quality of life and menopause
The common conception of QoL was originally believed a useful assistant to 
conventional conceptions of health and functional status. An ideal health evalu-
ation, therefore, would take account of an assessment of the patient’s physical 
health, a measure of physical, social, and psychological functioning, and a measure 
of QoL. Such an assessment would include main physical, psychological, social, 
and spiritual dominions of life. QoL is defined as individuals’ perception of their 
position in life in the context of the culture and value systems in which they live and 
in relation to their goals, expectations, standards, and concerns. It is a wide-ranging 
concept influenced in a multifaceted way by the persons’ physical health, psycho-
logical status, degree of independence, social interactions, and their connexion to 
relevant features of their environment [18].
Transition into menopause is related to different physical and mental changes 
that may affect women’s health. Studies show that the physical, psychological, 
social, and sexual changes in menopause have an adverse effect on women’s qual-
ity of life. It has been expressed that 96% of women have menopausal complaints 
and their quality of life is affected not only physically and psychologically but also 
socially. It is reported that the QoL of women is especially unfavorably marked in 
the perimenopausal and early postmenopausal periods. Simultaneously with the 
growing extension of the expected life span, the time that is spent in the climacteric 
period is also growing. Warranting that women having an elevated QoL in this 
phase may be made likely by showing the complications they suffer, along with 
associated aspects and defining the status of their QoL [19].
Apparent QoL is difficult to determine and there is no global conformity on 
how it should be measured. Objective dimensions of health condition (HRQoL) 
may not obtain the patient’s judgment of overall life satisfaction. QoL can be 
expressed as an indication of an individual’s belief about functioning and achieve-
ment. HRQoL may be seen as the individual’s perception about her physical, 
cognitive, and mental health as well as social status. Valuations of overall QoL 
for climacteric patients require taking in count physical symptoms (hot flushes, 
night sweats, and urogenital atrophy), psychological symptoms (depression, 
mood swings, irritability, and anxiety), and life conditions (functioning at work 
and other social scenarios). Thus, overall QoL may include four main factors: 
occupational, health-related, sexual, and emotional. Consideration of HRQOL is 
also influenced by women’s augmented risk of multiple chronic diseases related 
to menopause, including osteopenia, osteoporosis and associated fractures, and 
cardiovascular disease [20].
Symptoms experienced during menopause and sociodemographic charac-
teristics affect the quality of life in postmenopausal women. In younger, symp-
tomatic, postmenopausal women, health-related quality of life (HRQoL) may be 
significantly diminished. However, quality of life after menopause is influenced 
by many additional, non-menopausal factors. Management alternatives to manage 
climacteric symptoms and all measures amending adverse non-hormonal aspects 
could increase HRQoL among climacteric women. This includes marital and sexual 
therapy as well as psychosocial actions. Menopausal hormone therapy (MHT) 
may reverse this decline of HRQoL if it is due to postmenopausal-estrogen insuf-
ficiency. In contrast, when MHT is recommended to asymptomatic younger and 
older climacteric women, no progress in HRQoL can be obtained. Health status 
and QoL are not linearly related. Recently, there has been a rising alertness of the 
features of QoL and aging. QoL is a subjective factor. Therefore, open enquiring is 
the most easy and proper way of adding data about how patients feel and function. 
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Existing measures of QoL try to quantify the effect of health deficiency through 
several physical, psychological, and social factors [1].
Symptoms experienced during menopause and sociodemographic characteris-
tics affect quality of life in postmenopausal women. Hot flushes impact the daily 
activities of most postmenopausal women, especially those with more frequent/
severe symptoms. The impact in daily life of menopause symptoms (hot flushes, 
vaginal dryness, cognitive function, anxiety and depression, urinary complaints, 
uterine bleeding, low sexual desire, among others) can be seen in work, social 
and leisure activities, mood, concentration, sleep quality, marital and sexual 
satisfaction, and the level of daily energy [1]. Vasomotor and sexual complaints 
have a major impact in the first 5 years after menopause and psychological, and 
physical symptoms have more effect on QoL in women with more than 5 years of 
menopause [19]. Quality of partnership, physical activity, weight changes, and 
education are particularly important for HRQoL during the menopausal transi-
tion. Women who decreased their physical activity had deterioration in HRQoL 
compared with women, whose physical activity remained stable. Inversely, women 
who increased their physical activity improved their HRQoL. These improve-
ments are likely mediated through greater thermoregulatory control in response 
to increases in core temperature and enhanced vascular function in the cutaneous 
and cerebral circulations. Mechanisms involved include a decreased hypothalamic 
endorphin concentration and declining estrogen production, whereby the release 
of norepinephrine and serotonin is facilitated. Most likely, improvement of HRQoL 
by exercise is secondary to the reduction of hot flushes. Exercise may ameliorate 
vasomotor symptoms by increasing the presence of hypothalamic and peripheral 
b-endorphin production [1].
The decrease of HRQoL in women suffering from any severe acute or chronic 
disease may be superimposed on the decrease of HRQoL induced by menopause 
itself. The impact of coronary heart disease, a frequent disease in postmenopausal 
women, will serve as an example. Coronary risk factors are highly prevalent among 
older women and the main cause of death. About one-third of middle-aged women 
have hypertension. Over one-quarter of these are cigarette smokers, over one-
quarter are also overweight. Modifiable coronary risk factors tend to predominate in 
populations of lower socioeconomic status as well as lower educational levels. Other 
long-standing metabolic consequences of the climacteric include osteoporosis and 
osteoporotic fractures skin changes, the general aspects of weight gain and obesity 
as well as degenerative disease of the central nervous system (CNS). Investigation 
on the effect of estrogen and other sex hormones on the vascular system, immunity, 
CNS performance, or musculoskeletal disease is constant, with particular allusion 
to the cellular level. Awareness of symptoms, nevertheless, and their effect on the 
everyday life of women, will support the care-giver in given women with proficient 
care and enduring specialized aid throughout the aging process. It will indeed be 
appropriately supportive to offer objective evidence about an individual’s symptoms 
of the climacteric woman that might affect her QoL [1].
The effect of menopause on body fat distribution is uncertain, but some studies 
suggest that menopause is associated with an accumulation of central fat and intra-
abdominal fat. Although weight gain during menopause is a normal phenomenon, 
few studies have proved the relationship between menopausal status and weight 
gain. The relationship between obesity and health-related quality of life (HRQoL) 
has been widely investigated that obesity has been associated with compromised 
HRQoL and psychological well-being. The prevalence of obesity and obesity-
linked illnesses is increasing, particularly in the urban environment. Therefore, 
poor physical functioning and reduced QoL attributable to being overweight are 
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important in terms of public health and should be addressed by preventive mea-
sures and interventions to promote healthy living. Most general population studies 
conclude that QoL in many persons with obesity is suboptimal. The association 
between obesity and HRQoL is stronger in women than in men, in both physical 
and mental or psychosocial dimensions [21].
Many tools have been developed for the assessment of the HRQoL in aging and 
climacteric women. Myra Hunter developed her Women’s Health Questionnaire 
(WHQ ) as a self-reported measure of physical and emotional experience and func-
tioning of women aged 45–65 years. The WHQ was used both in epidemiological 
and intervention studies. A revised WHQ comprises six domains with 23 items. The 
MENQOL was developed by a group of researchers from Canada during the mid-
1990s. The final 32-item menopause-specific HRQoL instrument encompasses four 
subscales (physical, vasomotor, psychosocial, and sexual) plus one overall HRQoL 
item. As with the WHQ , no overall score can be obtained, because the relative 
contribution of each domain to such an overall score is unknown. The Menopause 
Rating Scale (MRS) was initially developed to provide the physician with a tool to 
document specific climacteric symptoms and their changes during treatment. The 
original physician-based scale was revised concerning the layout and some adjust-
ments regarding the number, structure, and wording of items; these were made to 
support applicability as a self-administered questionnaire.
The MRS finally went through factor analysis of 11 standardized items 
encompassing 3 domains: psychological, somato-vegetative, and urogenital 
dimensions. The scoring is based on a five-point Likert scale, ranging from 
no symptoms to mild, moderate, marked, or severe complaints. It should be 
regarded as a brief and compact instrument, easy to complete and to score, 
and suitable for routine controls. It covers the key complaints of women during 
and after menopause. It is, however, not tailored to detail specific therapies to 
the needs of each individual woman. A large variety of linguistic validations 
of the MRS has created an excellent international response and acceptance [1]. 
Menopause-specific quality of life (MENQOL) talk about perceptions of women 
living with the menopausal change or premature postmenopause, employing 
methods to measure, bother and interference with aspects of daily living related 
to symptoms presented throughout the menopausal transition. The MENQOL 
questionnaire and the Women’s Health Questionnaire (WHQ ) clarify the meno-
pause-detailed valuation of QoL [22].
Menopausal Hormone Therapy (MHT) for menopausal symptoms includes use 
of estrogens, alone or in combination with aprogestogen, tibolone or a blend of 
estrogens, and selective estrogen-receptor modulators (SERMs). Although MHT is 
the best effective treatment for menopausal vasomotor symptoms, it has no indica-
tion for all women, such as those with a personal history of breast cancer [23]. 
Despite the negative impact that the results of the WHI study had over patients’ and 
clinicians’ attitudes toward menopausal hormone therapy (MHT) [24]; to date, it is 
still the most effective option for the management of hot flushes and other symp-
toms related to the menopause. In fact, there is a current consensus to recommend 
the use of lower dosages and the non-oral route. Emerging data associated to effects 
of hormone therapy for MENQOL have continued to progress during this period, 
as well as a growth of novel investigations. Some search complementing evidence 
for MHT and QoL measure are the menopause strategies: finding lasting answers to 
symptoms and health (MS-FLASH) trials, the selective estrogens, menopause, and 
response to therapy (SMART) trials assessing results of combinations of conjugated 
estrogen therapy (CET) with bazedoxifene, a selective ET receptor modulator 
(SERM), and Kronos Early Estrogen Prevention Study trial. Besides, researchers 
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have conducted search analyzing use of MHT that contain a diversity of progestins 
(drospirenone) [22].
New and innovated technologies for hormonal delivery may have a better 
impact on MHT compliance shortly. Providing a combination of E/P in a parenteral 
monthly formulation with the presently suggested lower dosages and using a new 
technology that offers persistent plasmatic levels over time, will have a positive 
long-term outcome on compliance. It has just reported an optimistic pilot experi-
ence in taking care of vasomotor and urogenital atrophy symptoms with three 
low-dose continuous sequential monthly parenteral formulations of 17b-estradiol 
(E)/progesterone (P) employing innovative non-polymeric microsphere technology 
[25]. Later was presented the short-term effect of the same proposed schemes over 
secondary endpoints (menopausal symptoms and QoL). After 6 months, there was 
an improvement of menopausal symptoms for all groups [26].
The non-hormonal treatment of menopausal symptoms possibilities includes 
daily life modifications, régime and food supplements, non-hormonal drugs, and 
behavioral, alternative, or complementary therapies. While various are effective, 
for others the data are doubtful. Though, for women who cannot or do not desire 
to take estrogens, non-hormonal managing is now a real option. For instance, soy 
isoflavones, coumestans, and lignans are all phytoestrogen supplements that have 
been suggested as substitutes to MHT for vasomotor symptoms. Phytoestrogens are 
present in soybeans, hops, flaxseed, fruits, vegetables, whole grains, and legumes. 
These options have been proposed to have estrogenic or anti-estrogenic effects in 
human beings. Extracted or synthesized soybean isoflavones have been discovered 
to diminish hot flush occurrence and seriousness. Nevertheless, a latest meta-anal-
ysis establishes that there is no convinced evidence that phytoestrogen supplements 
successfully reduced the frequency or severity of vasomotor symptoms in peri-
menopausal or climacteric women. A non-hormonal pharmacological possibility 
is selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine-
reuptake inhibitors (SNRIs), which have been suggested as an option to MHT 
for treatment of hot flushes. SSRIs, (paroxetine, escitalopram, citalopram, and 
sertraline) have been proven and are helpful in falling both frequency and severity 
of hot flushes. Paroxetine appears to have the best evidence base of efficacy and was 
approved by FDA for the treatment of menopausal hot flushes. SNRIs (venlafaxine, 
desvenlafaxine) have been tried to treat menopausal symptoms, mainly in women 
in whom MHT is not indicated, and desvenlafaxine is approved for vasomotor 
symptoms associated to menopause in Mexico [23].
4. Menopause and hormones
Menopause is a period of life when the ovaries are depleted of oocytes and the 
cyclical action of gonadotrophins, peptides, and steroids is disappeared. Age at 
menopause reveals the complex networks of health and socioeconomic aspects 
involving ethnicity, diet, education, oral contraceptive use, weight, occupation, 
exposure to endocrine disturbing substances, alcohol consumption, smoking, and 
physical activity [27]. Menopause is an indicator event in a woman’s life that marks 
the end of reproductive capability. Although the age-related loss of vaginal bleeding 
in women has been described throughout history has been recognized the dramatic 
reduction in the amount of follicles within the ovary as a function of age, deter-
mining that the loss of both germ cells and the hormone-producing cells that help 
them is critical to the disappearing of menstrual function in women. Menopause is 
identified by the final menstrual period (FMP), but this diagnosis can only be made 
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retrospectively after a year of amenorrhea and happens at an average age of 51 [28]. 
In Mexico, the average age is 47.6 [29].
The development of reproductive aging, though, is slow, starts before the FMP, 
and can be defined as limiting (1) an early phase in which compensatory modifica-
tions in the hypothalamus, hypophysis, and ovary facilitate the preservation of both 
reproductive capability and gonadal hormone secretion; (2) an interval categorized 
by clear irregularity in follicle progress, ovarian secretion, and resulting symptoms 
precede to the FMP; and (3) constant and low ovarian hormone secretion [28]. The 
menopause has important effects on the functions of endocrine, cardiovascular, 
skeletal, immune, and genitourinary systems. Gonadal hormones affect much of the 
processes mainly by their effects on steroid binding proteins and receptors, but the 
changes in lifestyle with aging are also influential [27]. Detailed ultrasonographic 
show the changes in ovulatory function with reproductive aging largely define the 
hormonal changes, menstrual cycle patterns, and symptomatology that occur as the 
FMP approach [30].
Reproductive aging in women is mainly produced by the continuing, and finally 
quickening deficit of ovarian follicles. The related decay in inhibin B secretion 
from the ovaries ends in the disappearing of negative feedback on FSH. Inside the 
ovary, FSH stimulated follicle growth and estrogen synthesis and secretion. With 
additional follicle loss, these compensatory hormonal processes are no longer 
enough and follicle development come to be irregular in advance to additional loss 
of ovarian function results in the stable but very low estradiol levels that exemplify 
the postmenopause [28].
Several of the biochemical variations at climacteric period are due to estrogen and 
or progesterone diminution. Both steroids act through cytoplasmic receptors and two 
receptors for respectively steroid, alpha, and beta (ER-α and ER-β; PR-α and PR-β) 
are now recognized, occasionally antagonize each other. Isoforms of every receptor 
be present that have dissimilar tissue expression conformations and purpose which 
marks gene expression in normal and tumor tissue, therefore ligand treatment. ER-α 
is largely expressed in reproductive tissues, breast, kidney, bone, adipose tissue, 
and liver. ER-β is existent in ovary, CNS, lung, colon, kidney, and immune system. 
PR-α and PR-β are almost equal in configuration with the exception of PR-β having 
a supplementary 164 amino acids at the N terminus. PR-α and PR-β are expressed 
similarly in human tissues [27].
The 2001 Stages of Reproductive Aging Workshop (STRAW) and the 2011 
STRAW + 10 proposed nomenclature and a staging system for ovarian aging 
including menstrual and qualitative hormonal criteria to define each stage. The 
STRAW staging system is extensively considered in the gold standard for describ-
ing reproductive aging through menopause. The menopausal shift signs a stage of 
physiologic changes as patients get close to reproductive senescence. Proof endorses 
the clinical significance of the transition for many patients as a phase of progressive 
fluctuations in health and QoL (i.e., vasomotor symptoms, insomnia, and MDD) 
and longer-term variations in numerous physical consequences (i.e., urogenital 
symptoms, bone, and lipids) that might impact women’s QoL and the probability of 
healthy aging. As a standardized staging scheme for reproductive aging, STRAW is a 
huge influence to patient’s health investigation by giving trustworthy categorization 
of menopause status for investigations of midlife patients. Significantly, STRAW 
helped investigation that proposed to differentiate the health effects of ovarian 
versus somatic aging. The STRAW staging system also helps as a clinical instrument 
for women and their healthcare providers to monitor the valuation of fertility, 
contraceptive needs, and healthcare decision making [31].
STRAW distributed the adult female life into three extensive phases: repro-
ductive, the menopausal transition, and postmenopause. The late reproductive 
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phase indicates the time when fecundability starts to decay and during which a 
woman might observe variations in her menstrual cycles. Given that significant 
endocrine factors start to change before obvious variations in menstrual cyclicity 
and that these endocrine fluctuations are crucial to fertility assessment. Early 
menopausal evolution is discernible by amplified inconsistency in menstrual cycle 
extent, conceptualized as a persistent difference of 7 days or more in the length 
of consecutive cycles. Persistence is defined as recurrence within 10 cycles of the 
first variable length cycle [31].
Cycles in the initial menopausal transition are also defined by high but varying 
early follicular phase FSH levels and low antimüllerian hormone (AMH) levels 
and antral follicle count (AFC). The late menopausal transition is apparent by 
the manifestation of amenorrhea of 60 days or longer. Menstrual cycles in the 
late menopausal transition are exemplified by augmented inconsistency in cycle 
length, severe changes in hormonal amounts, and elevated frequency of anovula-
tion. In this stage, FSH levels are occasionally raised into the menopausal range 
and sporadically within the span typical of the initial reproductive years, mainly 
in relationship with elevated estradiol levels. The elaboration of international 
criteria and the accessibility to fundamental population-based information now 
allow the definition of quantitative FSH criteria, with levels greater than 25 IU/L 
in a random blood draw typical of being in late transition, founded on actual 
international pituitary criteria that approximate more than 40 IU/L in the earlier 
used urine-based gonadotropin standards. First-hand analyses should be initiated 
to verify this reference, and investigators and clinicians should prudently estimate 
the proper FSH value, subject on the test they employ. Founded on investigations 
of menstrual calendars and on changes in FSH and estradiol, this phase is expected 
to persist, on average, 1–3 years. Vasomotor symptoms are probable to be pres-
ent during this phase. Novel data on the routes of change in mean levels of FSH 
and estradiol indicate that FSH continues to rise and that estradiol continues to 
decline until around 2 years after the FMP, after which the levels of each of these 
hormones stabilize. The late postmenopause characterizes the interval in which 
supplementary variations in reproductive endocrine function are more delimited 
and processes of somatic aging become of principal worry. Symptoms of vaginal 
dryness and urogenital atrophy become progressively more prevalent at this time. 
Nevertheless, several years after menopause, it has been perceived that there may 
be an added drop in levels of FSH in very old women; forthcoming investigations 
will be required to define whether a supplementary stage is necessary close to the 
end of life [31].
Investigations in younger and older climacteric patients insinuate that con-
sequences of aging on the hypothalamus and pituitary are present and those are 
autonomous of the disappearance of steroid feedback. Following menopause 
there is a 30–40% reduction in LH and FSH between the ages of 50 and 75. Lie 
beneath these gonadotropin differences are intricate consequences of aging on 
GnRH secretion, with a 22% reduction in GnRH pulse frequency that is slightly 
balanced by a 14% rise in the total quantity of GnRH secreted over that owing to 
the deficit of ovarian function only. There are also age-related outcomes at the 
pituitary, with a 30% lessening in both LH and FSH responses to GnRH in older 
in comparison with younger climacteric patients. Estrogen-negative feedback 
at the hypothalamic point continues complete in older contrasted with younger 
postmenopausal patients; low-dose estrogen prescription is related with a sub-
stantial descent in circulating levels of LH, FSH, and free alpha-subunit and a 
parallel reduction in the total concentration of GnRH, with no effect on pulse 
frequency. Adding of progesterone diminished pulse frequency in younger and 
older  climacteric patients with an associated reduction in total quantity of GnRH. 
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The outcome of estrogen-negative feedback on the LH response to GnRH is not 
predisposed by aging even though the FSH response to GnRH is weakened with 
aging. Numerous reports have proposed that sensitivity to estrogen-positive  
feedback may be absent with aging in women [28]. Hormone measurements 
other than FSH during the perimenopause are usually considered to be of little 
 diagnostic value. The transition may take four or more years [27].
In the late perimenopause, where extended cycles (≥60 days) predominate, 
60–70% cycles are anovulatory. Regarding the steroid hormone secretion patterns, 
when ovulatory cycles do happen, the cycle may seem normal, overlaid on one 
another or have a prolonged follicular phase named as a lag phase. While the initial 
perimenopause is considered by instabilities in the timing and regulation of ovula-
tion, the advanced perimenopause is distinguished by rareness of ovulation derived 
to the original ovarian follicle reduction. In the late perimenopause, although 
AMH has decreased to imperceptible levels, inhibin B frequently persists measure-
able, particularly if there is still residual follicle function. Both gonadotropins are 
considerably high and show substantial cyclical differences. FSH amounts can be 
at their most irregular throughout the late perimenopause. The function that very 
low AMH amounts to participate in the interference of ovulatory function in the 
perimenopause continues indeterminate but given its close link with the total non-
growing follicle (NGF) pool and primordial follicle recruitment and the intricacy of 
underlying follicle wave action, it is likely to be crucial [30]. In the initial 1–2 years 
after the FMP, intermittent follicle growth is obvious in single women. Harmonious 
with these studies, epidemiologic reports employing sensitive estradiol assays 
prove a farthest decrease from the FMP to the estradiol lowest point 2 years ahead. 
Subsequently, estradiol levels persist low and stable. FSH levels also continue steady 
between 2 and 8 years after the FMP but decay over time such that FSH drops by 
30% by around age 75, as does LH. Nevertheless women are no longer concerned by 
irregular bleeding or breast tenderness, hot flashes may continue for up to 7 years 
after the FMP, and with lengthy hypoestrogenism, the genitourinary syndrome 
(GSM) of menopause may appear as a novel clinical symptom [28].
5. Menopause and associated health problems
The transition to menopause is characterized mainly by elevated levels of 
follicle-stimulating hormone (FSH) and low serum levels of estradiol, which gives 
rise to the presence of the characteristic symptoms (hot flashes, menstrual irregu-
larities, sleep disruption, mood swings, headache, and genitourinary syndrome) 
[32]. 80% of women suffer physical and psychological symptoms throughout 
menopause with different degrees of seriousness and influence on QoL [4]. 
Clinicians and women usually identify the transition to menopause by the onset of 
menstrual irregularities [5, 6]. This period called perimenopause is variable but can 
range from 5 to 10 years before menopause.
The Study of Women’s Health Across the Nation (SWAN) is a longitudinal, 
epidemiologic study designed to examine the physical, biological, psychological, 
and social changes during their intermediate years when they are suffering from 
menopausal transition that evaluated a total of 3302 women from different ethnic 
among 42 and 52 years old with a follow up for 15 years. The scientific areas of study 
assessed: bone mineral density and body composition, cardiovascular measures/risk 
factors, ovarian markers, vaginal, urogenital and sexual health, physical function-
ing, sleep quality, psychosocial factors, and epidemiologic factors. The results of this 
study contributed to define The Stages of Reproductive Aging Workshop (STRAW), 
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a staging system that categories reproductive life stages of adult women en three 
main categories: reproductive, menopausal transition, and postmenopause [33].
During the late reproductive year’s, progesterone levels in the luteal phase 
decrease and the follicular phase is shortened from 14 to 10 days, including the 
decrease in inhibin B and a slight increase in FSH levels with preserved levels of 
estradiol, which gives rise to menstrual irregularities. The levels of antimüllerian 
hormone (AMH) and the count of antral ovarian follicles diminish too [32]. As 
time goes (around 2 years since last menstrual period), the FSH levels continue to 
rise and estradiol levels start falling and for the next 3–6 years estradiol, AMH and 
inhibin B levels are even lower, at this time is when the symptoms of genitourinary 
syndrome (GSM) could be more severe [32, 34, 35]. Contraception should be a part 
of any counseling during the menopausal transition due to the presence ovulatory 
cycles that can still occur until 12 months of amenorrhea have occurred [32].
The body mass index (BMI), lifestyle factor like tobacco use could influence the 
timing of the physiologic changes, but not in the path of change in bleeding patterns 
or hormonal levels with reproductive aging [31]. Some situations like the surgical 
menopause caused after a hysterectomy may not let us know when is the patient is 
in transition to menopause, the only way we could evaluate objectively this stage 
of life is by endocrine markers of ovarian aging, it is necessary to mention that 
3 months after surgery high levels of transient FSH may occur, so for an accurate 
diagnosis, a new measurement of estradiol or serum FSH is required [36].
The bleeding patterns may not be a reliable parameter for evaluating reproduc-
tive aging owing to different endocrine disorders like polycystic ovarian syndrome 
or any other chronic illness or medications like cancer treatment among other 
situations that can also affect menstrual patterns or even cause amenorrhea [32]. 
It is well known that alkylating agents used as chemotherapeutic medication may 
lead to temporary elevated levels FSH and a decline of AMH and ovarian antral 
follicle count (AFC), but with time menstruation may resume [37–39]. Women 
in treatment with tamoxifen may also have altered hormone levels and abnormal 
bleeding patterns [40].
During this life stage period, serum cortisol levels also increases as well as 
adrenal androgen levels (androstenediol, dehydroepiandrosterone sulfate). In 
thyroid function for the moment, there is no information about disorders related 
to menopause so far [32]. After the cessation of ovarian function, the production 
of estrogen comes from the aromatization of androgens in the ovarian stroma 
and, in less quantity, from extragonadal sites mainly the adipose tissue. Hence, it 
is expected that obese women present vasomotor symptoms more frequently and/
or intensively.
Hot flashes, which may be accompanied with some other symptoms like flushing 
of the face, neck, and upper chest; palpitations; chills; and/or anxiety are some of 
the vasomotor symptoms [32] that occurs in up to 80% of women, frequently asso-
ciated with diminished sleep quality [41, 42] irritability, difficulty concentrating, 
reduced quality of life (QoL) [43], and poorer health status [35]. Some researchers 
are looking for the relationship with the presence of hot flashes with markers of 
cardiovascular risk, in order to identify a vulnerable vascular phenotype [44].
Of all possible etiologies of headache, tensional headache is the most com-
mon. Migraine-type headache can increase during menopause due to hormonal 
changes. Tensional-type headache usually shows a favorable response to non-
steroidal therapy and can be prevented altogether with tricyclic antidepres-
sants instead of hormonal therapy alone. Non-cyclical hormonal therapies are 
recommended to minimize headache due to hormonal treatment. Women who 
suffer migraine headache with aura or other risk factors of CVD can benefit from 
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progesterone-only therapy, like the levonorgestrel intrauterine system, etonoges-
trel subdermal implant, depo-medroxyprogesterone acetate, or progestin-only 
contraceptives [32].
The symptoms of genitourinary syndrome (GUS), which may comprise signs 
and symptoms associated to the hypoestrogenism of the menopause involving 
changes to the labia, vagina, urethra, and bladder and includes vulvovaginal 
atrophy [45]. Symptoms are genital dryness, burning, and/or irritation; sexual 
symptoms of diminished lubrication and pain; and urinary symptoms of urgency, 
dysuria, and recurrent urinary tract infections (UTIs) [35]. Signs include changes 
in the skin consequently of the reduction blood flow to the vagina and vulva, the 
external genitalia reveals less pubic hair and less elasticity of the vulvar skin with 
introital narrowing and possible changes in the architecture, such as the loss of the 
labia minora, usually we could appreciate this changes about 3 years after meno-
pause, although approximately 20% of women may report some symptoms in the 
early or late transition of menopause [46]. Topical estrogen is the best treatment 
for the relief of vulvovaginal symptoms and current therapeutic therapy, among 
the options for topical administration include creams, gel, vaginal tablets, or even 
vaginal ring [34]; other therapeutic options are vaginal lubricants and moisturizers. 
It is necessary to mention that also systemic estrogen preparations with or without 
progesterone provide excellent vaginal therapy [32].
Low-dose vaginal estrogen preparations are effective and generally safe treat-
ments in women with actual diagnosis or history of breast cancer and treatment 
with tamoxifen, that with the non-hormonal treatments did not present relief of 
the symptomatology, there is lees information about treatment with aromatase 
inhibitors, taking into account that vaginal estrogen preparations can be absorbed 
systemically in a minimal amount. Less data are available on the creams containing 
conjugated estrogens than on those containing 17B-estradiol [47].
Menopause is associated with an increase in skeletal, joint, and muscle symp-
toms [43]. Estrogen binds on estrogenic receptor on joint tissues, protecting their 
biomechanical structure and function and maintaining overall joint health, but the 
exact effect of estrogen on osteoarthritis remains controversial [48–50]. Arthralgias 
increase with age, also rheumatic disorders incidence has an augment. Women who 
are obese or depressed may have marked symptoms, nevertheless it seems to be an 
association with joint pain or stiffness and menopausal transition, these symptoms 
could be alleviated with estrogen therapy alone or with combination therapy of 
estrogen and progestin, women in the WHI and some other studies have shown less 
joint pain or stiffness compared with those on placebo [32, 51].
In 2010, it was estimated that 21% of women in the European Union between 
50 and 84 years old have osteoporosis. Osteoporosis, along with osteoarthritis, 
sarcopenia, and frailty, is considered a part of the so-called musculoskeletal aging 
phenotype. Adverse outcomes such as falls, fractures, functional deterioration, and 
increased morbidity can impact quality of life. The clinical complications of osteo-
porosis are fractures of the hip, wrist, and vertebral bodies. Worldwide, 8.9 million 
fractures occur annually due to osteoporosis, resulting in a fragility fracture every 
3 seconds, which is associated with pain and decreased physical and social function 
in menopausal women [52].
Cardiovascular disease (CVD) is main etiology responsible of mortality in 
postmenopausal population. Menopause, itself, increases the risk of CVD no mat-
ter the age [53]. There is evidence that the use of estrogenic therapy has beneficial 
effects in cardiovascular mortality in many ways, some of them includes the 
reduction diminish of low-density lipoproteins levels and increased levels of high-
density lipoprotein as well as the improved endothelial function in the coronary 
vasculature [32].
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The reanalysis of older studies such as the WHI study and the recent studies sug-
gest that in case of no contraindication, the benefits of hormone therapy outweigh 
its risks, with fewer CVD events in younger versus older women [54].
Venous thromboembolism (VTE) has an augmented incidence when is related to 
the usage of hormonal therapies for menopause, it is supposed to increase twofold 
or threefold the risk, presenting a higher risk with oral formulations. Transdermal 
preparations of estrogen or estrogen and progestins combined and vaginal estrogen 
preparations did not appear to increase the risks of VTE [55]. In a meta-analysis of 
women who started HRT less than 10 years following menopause beginning or who 
were younger than 60 years, robust sign of augmented jeopardy of VTE was seen in 
the horn therapy group related to placebo (RR 1.74; 95% CI, 1.11–2.73) [56]. Minor 
doses of oral ET may give reduced VTE risk than higher doses [57], but related RCT 
evidence is requiring.
Talking about hormone therapy and breast cancer may result controversial, 
the effect of hormone therapy on breast cancer risk may depend on the type of the 
formulation, dose, and duration regimen, route of administration, prior exposure, 
and individual characteristics [35]. In the WHI study, the incidence of breast cancer 
increased in the estrogen-progestogen cohort and decreased in the estrogen-only 
and placebo groups. Contrarily, hormone therapy users had more localized tumors 
and improved survival rates [32]. The NAMS do not recommended the prescription 
of systemic hormone therapy for survivors of breast cancer, although selected cases 
may be discussed in conjunction with an oncologist after non-hormone options 
have been unsuccessful. If the patient refers moderate to severe GSM symptoms, 
low-dose vaginal estrogens, may be considered after a failed trial of non-hormone 
therapies and with consultation of the oncologist in charge of the case [35]. Options 
for symptom management include non-hormonal moisturizers, vaginal estrogens, 
androgens, selective modulators of the estrogen receptor (SERM).
The skin is another target where the hypoestrogenism may have manifesta-
tions after menopause, it is altered by epidermal and dermal thickness, decreased 
collagen and elastin content, consequently more laxity and wrinkles, many women 
could also experience hair loss. Estrogen therapy may benefit wound healing 
through modifying inflammation, stimulating granulation tissue formation, and 
accelerating re-epithelialization. In studies, ET increased epidermal and dermal 
thickness, increased collagen and elastin content, and improved skin moisture, with 
fewer wrinkles [58]. It may be relevant to perform scrutiny studies to those women 
with hair loss like thyroid function, serum iron, and androgens in order to exclude 
other pathologies [32].
Cholelithiasis, cholecystitis, and cholecystectomy occur more frequently in 
women who take oral estrogen, presumably because of the first-pass hepatic 
effect after oral ingestion, so systemic hormone therapy should be prescribed 
with caution in women with known gallbladder disease [32, 35]. Estrogens 
increase biliary cholesterol secretion and saturation, promote precipitation 
of cholesterol in the bile, and reduce gallbladder motility, with increased bile 
crystallization [59, 60]. The transdermal route of administration could be the 
best option for this kind of patients [61].
In epileptic patients, menopause can present at earlier age. The cause of this 
could be related to the number of crisis the woman presents during her life and the 
anticonvulsants she uses as treatment, specifically the ones that are metabolized by 
the hepatic enzyme cytochrome p450, which also affects estrogen levels. It is com-
mon that women with epilepsy present seizures during the menopausal transition 
due to the hormonal fluctuations. It is important to note that some anticonvulsants 
agents may accelerate the metabolism of vitamin D, which possibly increasing the 
risks of osteopenia [32].
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6. Menopause and psychiatric disorders
One of the most consistent findings in psychiatry and psychology is that 
from menarche onwards females are at higher risk than males of developing both 
depressive and anxiety disorders. This sex difference remains robust throughout 
the lifespan, including old age, in the years beyond the reproductive period. The 
extensively reported link between puberty, the perinatal period, and menopause 
and excessive amounts of anxiety and depressive symptoms has directed several 
researchers to suggest the concept of reproductive-related disorders (RRDs). 
These psychiatric conditions are said to include a collection of disorders catego-
rized by their connection to reproductive processes and a maladaptive response 
by patients defined as being “genetically vulnerable” to normal hormonal varia-
tions. Other authors have examined not only the validity of such a construct, but 
also with respect to menopause, whether the marked cross-cultural changes in 
menopausal symptoms support this hypothesis [62]. While most women do not 
suffer negative mood consequences during menopausal transition, the risk to 
develop a major depression disorder (MDD) or depressive symptoms through-
out perimenopause is greater than in the premenopausal stage. Nevertheless, 
estimates from individual studies are diverse and hence the true risk estimate is 
unknown [63].
Depression (at both the symptom and the disease level) was related with poorer 
QoL, and that this link appeared to be stable over time. Getting better from MDD 
after treatment resulted in higher QoL, and the QoL improved even in patients 
who did not fully recover from the depressive episode. Since MDD affects QoL 
negatively irrespective of medical health, it is imperative to identify MDD and treat 
MDD patients. Consequently, it is importantly suggested that the health personnel 
in specialist and primary healthcare settings have a dual treatment perspective, 
including both psychological and physical health [64].
MDD is an incapacitating disorder, which frequently directs to substantial 
personal, societal, and economic costs. It affects 20% of adults in the US, and 
women are known for being overly more affected than men. The roots of such 
increased risk (2-fold on average) have been the subject of discussion and research 
from diverse perspectives—from epidemiology to genetics, from copying strategies 
to hormone variations. Windows of risk for MDD—also known as reproductive-
related depressive episodes—are probable linked with an augmented sensitivity 
suffered by several women to variations in the hormonal situation that happen 
throughout the luteal phase of their cycles, in the course of the postpartum phase, 
and/or throughout the menopause transition [65]. The odds-on depressive symp-
toms in perimenopause are doubled when associated to the premenopause and 
similar when compared to the postmenopause. Furthermore, throughout the peri-
menopausal phase, women describe a higher level of depressive symptoms severity 
when compared to the premenopause but not to the postmenopause. Moreover, 
there are signs for a positive connexion between vasomotor complaints and MDD 
during the perimenopause [63]. The presence of a menopause-associated depres-
sion, though, has been a more discussed issue. While it is irrefutable that variations 
in sex hormones and metabolism may affect QoL and overall functioning among 
certain women throughout midlife years, supplementary aspects—not connected to 
the menopause transition—may also influence MDD at this stage in life, involving 
comorbid medical illnesses, cardiovascular complications, vasomotor symptoms 
(VMS), sleep disorders, and stressful life events [65].
It is suggested that declines in estrogen around menopause are associated with 
declines in cognitive functioning as well as increased risk of depressive symptoms 
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and depressive disorders. Estrogen promotes neuronal growth and survival and acts 
on the cholinergic system, which is closely linked to cognitive functioning, par-
ticularly memory. Several studies suggest that cognitive function supported by the 
prefrontal cortex may be particularly sensitive to estrogen. Estrogen also has a role 
in neurotransmitter systems involved in depression. For instance, estrogen acts as a 
serotonergic agonist/modulator by increasing receptor binding sites, synthesis, and 
uptake in animal models and postmenopausal women and numerous longitudinal 
studies have demonstrated an increased risk of depressed mood in the menopausal 
transition compared to the premenopausal stage. The peri- and post-menopausal 
phases are linked with declines in delayed verbal memory compared to premeno-
pause. Moreover, the postmenopausal stage is linked with reductions in phonemic 
verbal fluency contrasted to perimenopause. Evidences propose that women are at 
a meaningfully augmented risk of getting MDD, as determined either by symptom 
inventory or by structured clinical interviews, in the peri- and post-menopausal 
stages than in premenopause [66].
The strengthened burden related with depression, at any point in time, is 
undisputable. Thus far, the existence and perseverance of symptoms of depression 
over time—symptoms that do not reunite criteria for MDD—may furthermore 
trigger anyway psychosocial difficulties and negatively impact total health. It is, 
consequently, significant that physicians maintain a tighter surveillance and regu-
larly re-evaluate the necessity for treatments to resolve depressive symptoms (e.g., 
low mood, reduced psychological energy and pleasure with habitual activities, 
and sleep problems), whether by employing pharmacologic options, behavioral/
lifestyle modifications, or supplementary alternatives. An important amount of 
both cross-sectional and prospective reports have discovered a possible relation-
ship between different menopause staging and the risks for depressive symptoms 
or MDD (new onset or recurrent). In general, information from cross-sectional 
trials show that symptoms of depression can be found by up to 70% of patients 
throughout perimenopause contrasted with almost 30% in premenopausal period. 
Longitudinal studies can describe the ideal approach for evaluating the link 
between reproductive staging and MDD, have also proposed an augmented risk 
(1.5- to 3.0-fold) for symptoms of depression during the menopause transition. 
This augmented risk was documented even between women with no preceding 
episodes [65].
Longitudinal trials have acknowledged possibility reasons for the presence of 
midlife MDD that appear persistent during the lifetime; they establish a continuum 
of risk for MDD and very likely function as regulating aspects. These aspects can 
be considered as: (1) demographic or socioeconomic (i.e., unemployment, low 
education, and being black or Hispanic); (2) health-related (e.g., greater body mass 
index, being a smoker, reporting poor health, and decreased functioning due to 
chronic medical diseases); and (3) psychosocial (e.g., reduced social care, record 
of anxiety, and one or more stressful life events). A prior MDD episode signifies 
the robust prognosticator for MDD throughout midlife years, while antecedents of 
mood symptoms with a hormone-related background (i.e., history of premenstrual 
syndrome/PMDD or postpartum depression) have been discreetly related to MDD 
during the menopause phase and initial postmenopausal years [65].
Investigators also explored the causative role of timing-related, context-related 
influences. Once more, results from cross-sectional and longitudinal investiga-
tion were valued foundations and helped to recognize in facilitating or triggering 
elements linked to menopause-related MDD. These elements include:  
(1) hormone changes (i.e., the occurrence of wider variations in follicle-stimulat-
ing hormone [FSH] and estradiol [E2] levels over time); (2) menopause-related 
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symptoms (e.g., existence and seriousness of VMS and insomnia); and (3) global 
health (current poor health and low functioning because long-lasting diseases). 
Psychosocial stressors (including poor social help and stressful life events—the 
latter not only considered by the severity and number of episodes but also 
founded on the timing of their manifestation linked to the menopause transition 
per se) [65].
Nevertheless, symptoms of MDD such as insomnia and low energy in midlife 
women may be challenging to differentiate from menopausal symptoms and may 
not often reveal an MDD. They might also be associated to symptoms of the meno-
pause such as VMS. This is reliable with the results of investigations of depres-
sive symptoms, which demonstrate that they are more frequent throughout the 
menopausal transition in comparison with both pre and postmenopausal stages. It 
is too reliable with the remark that depressive symptoms could growth around the 
postmenopausal phase as somatic symptoms progressively become less frequent 
and/or severe, and that they can improve with the management of central meno-
pausal symptoms such as VMS [67]. Also, psychological aspects as inter-personal 
relations, role, and sociocultural factors are defined as predictors for MDD during 
menopause [63].
Antidepressants are the first-line management of MDD around midlife years, 
mainly for women who had suffered numerous MDD episodes before (not always 
hormone-related) and women describing serious symptoms, important functional 
harm, and/or communicating suicidal thoughts. For recurrent episodes, a prior 
response to a particular antidepressant (agent or class) must lead the main resolu-
tion on what to use initially. For women facing MDD for the first time, women who 
never received treatment before, or women with antecedents of partial/no response 
to antidepressants before, current evidence confirmed the efficacy and tolerabil-
ity of numerous SSRIs and SNRIs at typical doses; there are trials on fluoxetine, 
sertraline, venlafaxine, citalopram, escitalopram, duloxetine, and desvenlafaxine 
[65]. In a recent published paper, data support further study of vortioxetine for 
treating menopausal depression and associated symptoms (VMS) and was generally 
well-tolerated [68].
The association between depression and menopause has been extensively 
explored, but the study of anxiety remains largely neglected. This is surprising, 
since symptoms of anxiety in the community are more common than those of 
depression, and generalized anxiety disorder (GAD) is the second most prevalent 
psychiatric disorder in the primary care setting [62]. Peri- and post-menopausal 
phases represent a window of risk for emergence of anxiety symptoms and 
disorders in the life cycle of adult women. Compared to MDD, anxiety symptoms 
and disorders remain mainly unknown throughout this period of a woman’s life, 
regardless of major impact on QoL if not identified and treated [69]. ‘Anxiety’ is 
a general term that can opaque the important difference between anxiety symp-
toms and anxiety disorders. Anxiety includes various symptoms such as feeling 
on edge, worrying, specific fears, and physiological arousal, and these may be 
distressing to the patient. Anxiety disorders, however, are defined by reference 
to specific criteria, and have much lower prevalence than anxiety symptoms. 
Most of the investigations reviewed measured anxiety symptoms, rather than 
anxiety disorders. There are physical correspondences between anxiety symp-
toms, particularly panic attacks and VMS. These include increasing sensations 
of heat through the chest and head, palpitations, and sweating connected with 
increased metabolic rate and noradrenergic dysregulation. It is not clear, however, 
whether body sensations of anxiety come first VMS or vice versa. The up-to-date 
data based on large community-based investigations proposes that psychological 
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symptoms during the menopause transition are related with known risk factors 
for anxiety and MDD, including stressful life events. An additional cognitive 
aspect that could be significant for comprehending the link between anxiety and 
VMS is that of catastrophic thinking. It is well-known that catastrophic thinking 
has a negative effect on perceived symptom seriousness in chronic health diseases. 
Those who report increased catastrophic thoughts also be likely to register poorer 
perceived control over their hot flashes [62].
Investigation has showed that sleep problems are frequent in middle-aged 
women, among whom the frequency of sleep problems has been observed to 
elevate in the period between pre- to peri- and post-menopause. While the 
precise process causing the connexion between elevated sleep troubles and the 
development of menopause is not completely recognized, it is probably linked to 
establish relationship between sleep disturbances. It has been found that VMS and 
depressed mood at this period in a woman’s life are closely related, women who 
suffer from VMS and sleep troubles, 30% of them were severely depressed. The 
results of one study were that the findings of this study show that difficulty in 
initiating sleep (DIS) is meaningfully connected with anxiety and non-restorative 
sleep (NRS) is meaningfully related with MDD in peri- and post-menopausal 
women in a clinical scenery. Those who describe suffering DIS or NRS may be 
highly probable to likewise be experiencing anxiety or MDD, correspondingly, 
signifying that management of these problems might increase the related insomnia 
symptoms in this group [70].
Multiple randomized controlled trials (RCTs) support the efficacy of SSRIs 
and serotonin-norepinephrine reuptake inhibitors (SNRIs) as first-line treatments 
for anxiety disorders. An analysis of 12 RCTs in panic disorder found a mean 
effect size for SSRIs relative to placebo of 0.55. In the case of GAD, response rates 
for SSRIs of between 60 and 75% are generally reported in RCTs, compared to 
response rates between 40 and 60% for placebo. Data suggest that post-traumatic 
stress disorder (PTSD) may be less amenable to current pharmacotherapy com-
pared to other anxiety disorders. A Cochrane review of pharmacotherapy for PTSD 
including 35 RCTs and 4597 participants did support the use of SSRIs as first-line 
medication treatment. The benzodiazepines (BZD) play a significant position in 
the management of several anxiety disorders; but, these drugs are commonly kept 
for second-line or accessory utilization because of their tolerability and abuse 
danger issues. BZD possess the benefit of a fast onset of action, tempting their 
employment premature in the process of management preceding to the onset of 
action of a co-administered SSRI/SNRI. Information backing the longer-term 
efficacy of BZD is more inadequate [71]. BZD inappropriate use (i.e., misuse and 
overuse) is a global public health concern. Regardless of existing information 
about augmented sensitivity to adverse effects in the elderly that should guide 
to additional carefulness. Only 30% of BZD prescriptions in these women are 
believed correct. The largely prevalent deficient conditions are disproportionate 
length and/or dosage of a medical prescription or self-medication, particularly 
in a situation where it would be contraindicated, for example, long-acting BZD 
in the elderly. Polypharmacy and comorbidities are the main risk factors. Results 
of benzodiazepines incorrect employment are falls, delirium and other cognitive 
dysfunction, acute respiratory failure, traffic accidents, abuse, addiction, and 
withdrawal symptoms. A developing apprehension is a possibly elevated risk of 
dementia. Opposing many physicians’ idea, discontinuation of long time BZD use 
in elderly patients is achievable, with acceptable psychotherapeutic or pharma-
cological options, and can direct to long-term abstinence [72]. Anticonvulsants, 
including gabapentin and pregabalin, have mixed data to support efficacy in 
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certain anxiety disorders. The data for second-generation antipsychotics (SGAs) in 
anxiety disorders are likewise mixed [71].
7. Menopause and sexual disorders
Female sexual dysfunction (FSD) and QoL are both multidimensional and 
have a bidirectional relationship across the reproductive life span and beyond. 
Methodological difficulties exist in assessing the actual prevalence of FSD because 
it is difficult to define the level of distress related to sexual symptoms. Around 
40–50% of women present at least one sexual symptom, and various disorders 
related with hormonal variations at menopause, such as vulvovaginal atrophy 
(VVA) and hypoactive sexual desire disorder (HSDD), have an important influence 
on sexual function and QoL. Sexual troubles reach a highest point at midlife, decay 
with age, and are importantly partner-associated [73].
Although in human’s sexual drive and performance are to some degree untied 
from sex hormones, menopause is the most studied medical condition in the frame-
work of FSD from a biological perspective since there is a strong state of hormonal 
deficiency. Both the substantial descent in blood estrogen levels with natural meno-
pause and the androgen reduction with age and, ultimately, with surgical meno-
pause, have been exposed to back, to a distinct degree, to sexual complains such as 
low desire, reduced excitement, dyspareunia, orgasm difficulties, and diminished 
sexual gratification. In contrast, menopause impacts psychologic and cognitive 
characteristics of sexuality throughout the variation in blood sex hormones, but 
this could be partially related on the particular antecedents of the specific patient. 
The mainly important factors are age, global and mental health, and attainment 
of reproductive objectives, education, body image, self-esteem, values and experi-
ences. Even length and quality of relationship, and global and sexual health of the 
sexual partner, are significant [73].
Sexual health and function are important goals in the management of meno-
pausal women. The majority of these women wants their sexuality to be a signifi-
cant part of their life and intensely desire to maintain a healthy and satisfactory 
sexual life. Nevertheless, the risk of having a disease that negatively affects sexual 
satisfaction and function as well as the risk for using prescription drugs that have an 
adverse impact in sexual function increases as women age. Although sexual dis-
satisfaction and dysfunction are highly predominant in peri- and post-menopausal 
women, few reveal their concerns to the health care provider. Age-related declines 
in sexual function may meaningfully reduce QoL [74].
Sexual function decays throughout midlife. The Study of Women’s Health Across 
the Nation and other related observed that this drop links with the menopausal 
period, including in women who experience hysterectomy. Though symptoms such 
as vaginal dryness rise during the same interval, variations in sexual functioning 
are unrelated of other symptoms linked to the menopausal period. Decrease in 
sexual frequency throughout this period of life is multifactorial. One main factor 
that women do not participate in sexual activity is absence of a sexual partner. 
Women who are more sexually active previously menopause appear to remain to 
participate in sexual behaviors during midlife, even with reduced “functional sex.” 
Lifestyle situations, including enough sleep and exercise, contribute to better sexual 
functioning during midlife [75, 76].
Vulvovaginal atrophy (VVA) is an important factor of genitourinary syndrome 
of menopause (GSM) and can end in postcoital vaginal bleeding, vaginal burn-
ing, irritation, and pain and distress with sexual behavior. Symptomatic GSM is 
frequently associated by reduced secretions from vulvar sebaceous glands and 
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decreased vaginal lubrication during sexual arousal. Hypo-estrogenic climacteric 
patients frequently face a change of the vaginal microbiome from lactic acid-
producing lactobacilli to gram-negative and -positive bacteria. This change in the 
vaginal microbiome causes raising of the vaginal pH, local immune changes, and 
increased cytokine synthesis, which exacerbates symptoms of vaginal dryness and 
burning and raise the risk of sexual dysfunctions.
Pelvic organ prolapses (POP) consist of descent of one or more woman repro-
ductive organs (anterior and/or posterior vaginal wall, the uterus or the apex of the 
vagina). The occurrence of pelvic floor relaxation rises with elderly and is theorized 
to appear from a mixture of connective tissue degradation, pelvic denervation, and 
devascularization, all of which prompt to prolapse. Dyspareunia, chronic pelvic 
pain, and poor self-image are related with POP. All of these undesirable physical 
alterations can destroy sexual desire and performance. Many medical problems, like 
diabetes, hypertension, and breast cancer, and their treatments, have been related 
with female sexual dysfunction. These conditions become more common as women 
move through midlife. Other medications have been associated with FSD. Among 
the most common responsible factors is the use of antidepressants. Although MDD 
itself is associated with sexual dysfunction, odds of sexual dysfunction are 4–6 
times higher for women taking an antidepressant. Sexual side effects are less com-
mon with bupropion and mirtazapine [75].
The presence of MDD and anxiety symptoms during the menopausal period is 
frequent. Mood disorders and sexual dysfunction are significantly comorbid, with 
25–75% of depressed women reporting sexual symptoms even when treating for 
other problems. It is important for health personnel to screen women with sexual 
complaints for MDD and anxiety disorders and be aware of that not all women with 
FSD have a MDD or an anxiety disorder. Common life stressors also have an unde-
sirable influence. Midlife women may be look after for children of their own, may 
have adult offspring at home, and/or may attend to aging parents. Job-associated 
stress and economic worries are also frequent. Health personnel must be familiar 
to the costs of life stressors and convince patients to cultivate stress diminution 
approaches, like mindfulness meditation or exercise.
Patients who suffered or are victims of violence and abuse are at augmented risk 
for FSD, with those who suffered sexual abuse, up to 44% of women over their life-
time, at predominantly elevated jeopardy. The link between abuse antecedent and 
FSD is not totally explicated by psychiatric disorders, such as MDD, anxiety, and 
post-traumatic stress disorder (PTSD). It is significant to utilize evidence-based, 
trauma-informed management tools to ask for these experiences when treating 
patients with FSD. Helping women preserve healthy sexual function with aging is a 
crucial element of preserving QoL into older adulthood [75].
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